Europe Edging Towards Electronic Prescribing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Europe Edging Towards Electronic Prescribing
Electronic prescribing has grown strongly in the US but its future as a European-wide approach in healthcare has been uncertain; new regulatory interest could change the playing field.


Pharmaceutical Technology Europe
Volume 23, Issue 10

The pharma industry's point of view

Electronic prescribing has important implications for the pharmaceutical industry because it will represent a change in physician behaviour. Pharma companies will need to determine how this trend will affect the prescribing of their products and ensure they provide physicians with adequate support (9). To maintain relationships with physicians, companies will need to be seen as experts in the electronic prescribing field themselves. In the US market, pharmaceutical companies have had to adapt very quickly to changes in physician attitudes and assess the strategy of their sales representatives who interact with physicians. In 2007, only 6% of physicians were prescribing electronically, but by 2010 this had jumped to over 30% (6)—and financial incentives from the US government to drive uptake mean that this trend will increase.

In Europe, although there has been discussion of the issues around electronic prescribing, there are few obvious signs that the pharma industry is preparing for large-scale uptake. It is inevitable that it will be eventually adopted, but no timeline can be predicted at the moment. The EMA's workshop will provide important direction to those interested in the concept and provide an official framework for the field to develop. Based on these outcomes, the European pharmaceutical industry will need to rapidly adapt to the changing prescribing environment. However, its knowledge of markets where electronic prescribing has proved a success should provide suitable experience to deal with changes in the European healthcare environment.

References

1. EMA, "Software development companies invited to express interest in workshop on electronic prescribing", News Release (UK, 2011).

2. Whitener Law Firm, P.A, "Prescription mistakes" (US, 2011). http://www.whitenerlawfirm.com/, accessed 9 Sept. 2011.

3. E. Cohen, "Don't be a victim of pharmacy errors", CNN (2007). http://edition.cnn.com/, accessed 9 Sept. 2011.

4. Guild of Healthcare Pharmacists, "Pharmacists EQUIP doctors with safety net when it comes to prescribing in hospital" (2009). http://www.ghp.org.uk/, accessed 9 Sept. 2011.

5. PMR, "Czech e-prescription system paperless only in name" (2011). http://www.ceepharma.com/, accessed 9 Sept. 2011.

6. E. John. "Pharma must prepare for e-prescribing closeup", Medical, Marketing & media (2011). http://www.mmm-online.com/, accessed 9 Sept. 2011.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology Europe,
Click here